GH Peptides for Fat Loss: What Research Shows
Growth Hormone and Body Composition
1.8x GH increase
MK-677 nearly doubled 24-hour growth hormone secretion in obese men, but fat mass stayed the same after 8 weeks.
Svensson et al., J Clin Endocrinol Metab, 1998
Svensson et al., J Clin Endocrinol Metab, 1998
View as imageGrowth hormone (GH) breaks down stored fat. That much is well established. So the logic seems obvious: boost GH with peptides, burn more fat. Dozens of online clinics sell this exact pitch, listing compounds like MK-677, ipamorelin, and AOD-9604 as fat-loss tools. The actual clinical data tells a more complicated story. The relationship between visceral fat and growth hormone involves feedback loops that peptides can disrupt in unexpected ways. Some GH peptides increase lean mass without touching fat stores. Others show fat reduction only in animals. And the one compound specifically designed to target fat, AOD-9604, failed its pivotal human trial.
Here is what seven key studies found when researchers put GH peptides to the test.
Key Takeaways
- MK-677 increased fat-free mass by ~3 kg in obese men over 8 weeks but did not significantly reduce total or visceral fat (Svensson et al., 1998)
- In a 2-year RCT of 65 older adults, MK-677 increased lean mass by 1.1 kg while the placebo group lost 0.5 kg, but fat mass also increased in the MK-677 group (Nass et al., 2008)
- AOD-9604 reduced weight gain by over 50% in obese rats and increased lipolysis without affecting insulin sensitivity (Ng et al., 2000)
- AOD-9604 does not bind the GH receptor, suggesting it works through a completely different mechanism than full-length growth hormone (Heffernan et al., 2001)
- GHRH treatment reduced visceral fat by 15-20% over 6-12 months in HIV-associated lipodystrophy, one of the few clinical settings with consistent fat reduction data (Stanley and Grinspoon, 2015)
- Ipamorelin releases GH without raising cortisol or prolactin even at 200x effective dose, but has no published human fat loss data (Raun et al., 1998)
How growth hormone breaks down fat
GH promotes lipolysis, the process of freeing fatty acids from stored triglycerides in adipose tissue. It does this primarily by activating hormone-sensitive lipase (HSL) in fat cells, increasing the release of free fatty acids into the bloodstream for oxidation. Visceral fat has more GH receptors than subcutaneous fat, which is why GH deficiency preferentially increases belly fat.[1]
Obesity itself suppresses GH secretion. Higher body fat leads to elevated free fatty acids and insulin, both of which inhibit GH release from the pituitary. This creates a cycle: more fat suppresses GH, less GH allows more fat accumulation. GH peptides aim to break this cycle by restoring pulsatile GH release.[2]
The question is whether restoring GH secretion with peptides actually reverses the fat accumulation.
MK-677 (ibutamoren): the most-studied GH peptide for body composition
MK-677 is an oral, non-peptide GH secretagogue that mimics ghrelin's action at the GHS-R1a receptor. It is the most extensively studied compound in this category for body composition effects.
8-week trial in obese men
Svensson and colleagues randomized 24 obese males (BMI >30, waist-hip ratio >0.95) to MK-677 25 mg daily or placebo for 8 weeks. MK-677 increased 24-hour GH secretion 1.8-fold and raised IGF-1 approximately 40%. Fat-free mass increased significantly by approximately 3 kg when measured by DEXA.[1]
The fat loss results, however, were absent. Total body fat and visceral fat did not change significantly. Basal metabolic rate increased at 2 weeks but faded by 8 weeks. And an oral glucose tolerance test showed impaired glucose handling at both 2 and 8 weeks.[1]
The study demonstrated that MK-677 is anabolic. It builds lean tissue. But 8 weeks of restored GH secretion did not translate into measurable fat reduction. The researchers noted that a higher dose or longer treatment might be needed. The 2-year follow-up study tested that hypothesis.
2-year trial in older adults
Nass and colleagues conducted a 2-year, double-blind, placebo-controlled trial in 65 healthy adults aged 60-81. MK-677 at 25 mg daily increased GH and IGF-1 to levels typical of younger adults.[2]
After one year, fat-free mass increased 1.1 kg in the MK-677 group while falling 0.5 kg in the placebo group (P < 0.001). Body weight increased 2.7 kg in MK-677 vs 0.8 kg in placebo. The extra weight was a mix of lean and fat tissue. Abdominal visceral fat did not decrease. Limb fat actually increased more in the MK-677 group (1.1 kg vs 0.24 kg, P = 0.001).[2]
Two-year results confirmed the one-year findings. MK-677 prevented age-related muscle loss and restored youthful GH levels. But it did not reduce fat. The appetite stimulation from ghrelin receptor activation likely offset any lipolytic benefit. Fasting glucose increased 0.3 mmol/L and insulin sensitivity decreased.
For anyone considering MK-677 for fat loss specifically, these two studies give a clear signal: it builds muscle, not burns fat. The comparison between GH secretagogues and exogenous HGH is particularly relevant here, because direct GH injection does reduce fat in GH-deficient patients while secretagogues show a more mixed pattern.
AOD-9604: the GH fragment designed for fat loss
AOD-9604 (amino acids 177-191 of human GH, plus a tyrosine at the N-terminus) was specifically engineered to isolate the lipolytic activity of growth hormone from its other effects.
Preclinical evidence
Ng and colleagues treated obese Zucker rats with oral AOD-9604 at 500 mcg/kg daily for 19 days. The treated animals gained only 15.8 g compared to 35.6 g in controls, a reduction of over 50%. Adipose tissue showed increased lipolytic activity. Critically, AOD-9604 did not impair insulin sensitivity, as demonstrated by euglycemic clamp testing.[3]
Heffernan and colleagues confirmed these findings in ob/ob mice treated for 14 days. Both full-length hGH and AOD-9604 reduced body weight gain, increased fat oxidation, and raised plasma glycerol (a lipolysis marker). AOD-9604 did not cause hyperglycemia or reduce insulin secretion, unlike hGH. Most telling: AOD-9604 does not bind the hGH receptor and does not stimulate cell proliferation. It works through a completely different pathway than growth hormone itself.[4]
The failed human trial
Despite promising animal data, AOD-9604 failed in a 24-week phase IIb clinical trial of 536 obese adults. The trial, completed in 2007, showed no significant weight loss compared to placebo. Metabolic Pharmaceuticals, the developer, subsequently halted development for obesity. The specific trial data was not published in a peer-reviewed journal, making independent evaluation difficult.
This disconnect between animal and human results is worth sitting with. Obese mice and rats responded well. Obese humans did not. Possible explanations include species differences in GH fragment metabolism, insufficient dosing, oral bioavailability challenges, and the complexity of human obesity compared to genetically obese rodent models.
AOD-9604 has since been reclassified as a food supplement ingredient in some markets and is sold as an injectable peptide through compounding pharmacies. Its regulatory status varies by country.
GHRH analogs: tesamorelin and visceral fat
Growth hormone-releasing hormone (GHRH) analogs take a different approach from GHS-receptor agonists like MK-677. Instead of mimicking ghrelin, they amplify the body's natural GH-releasing signal.
Stanley and Grinspoon reviewed the clinical trial data for GHRH treatment and visceral fat across multiple populations. In HIV-infected individuals with lipodystrophy, tesamorelin (a synthetic GHRH analog) reduced visceral adipose tissue by 15-20% over 6-12 months. The treatment also improved triglyceride levels and reduced markers of cardiovascular risk.[5]
Tesamorelin is the only GH peptide with FDA approval for a fat-related indication (HIV-associated lipodystrophy, approved 2010). Its effects are specific to visceral fat; subcutaneous fat does not decrease proportionally. This selectivity aligns with the higher density of GH receptors in visceral versus subcutaneous adipose tissue.
The HIV lipodystrophy population is unique, however. These patients have abnormal fat distribution driven by antiretroviral medications, not ordinary obesity. Whether tesamorelin produces similar visceral fat reduction in metabolically normal obese individuals remains a gap in the literature. The review notes that GHRH treatment increased GH secretion without altering pulse frequency, preserving physiological GH patterns rather than creating supraphysiological spikes.[5]
Ipamorelin: selective GH release, no fat loss data
Ipamorelin attracted attention because of its unusually clean pharmacological profile. Raun and colleagues demonstrated that this pentapeptide released GH with potency comparable to GHRP-6 in rats and swine, with one critical difference: it did not increase ACTH, cortisol, or prolactin even at doses 200 times higher than its effective GH-releasing dose.[6]
This selectivity is unique among GH secretagogues. GHRP-2 and GHRP-6 both elevate cortisol and prolactin alongside GH, which limits their therapeutic window. Ipamorelin's specificity for GH makes it theoretically attractive for body composition applications. Understanding how GH peptides differ in their muscle-building effects helps contextualize why selectivity matters for long-term use.
No published human trial has evaluated ipamorelin for fat loss or body composition. The compound has been studied primarily in gastrointestinal motility contexts. Its popularity in peptide clinics for fat loss is based entirely on the logic that selective GH elevation should promote lipolysis, not on direct evidence that it does.
Hexarelin: a fat-burning mechanism that bypasses GH
Rodrigue-Way and colleagues found that hexarelin, another GH-releasing peptide, depleted intracellular lipids in white adipocytes through a pathway that has nothing to do with growth hormone release. The mechanism involves CD36 (scavenger receptor), not the GHS-R1a receptor that mediates GH secretion.[7]
Hexarelin treatment of 3T3-L1 adipocytes increased expression of fatty acid transport protein (FATP), CPT-1 (which shuttles fatty acids into mitochondria), and uncoupling protein-1 (UCP-1, a thermogenic marker normally found in brown fat). Electron microscopy showed intense mitochondrial cristae formation, characteristic of tissues with high oxidative capacity. In mice, hexarelin-treated epididymal fat showed increased thermogenic markers, but this effect vanished in CD36-knockout animals.[7]
This study suggests that some GH peptides may affect fat metabolism independently of their GH-releasing activity, through direct interaction with fat cell receptors. The finding is limited to cell culture and mice. No human study has tested hexarelin specifically for fat loss. But it complicates the simple narrative that GH peptides burn fat by raising GH. The mechanism may be more direct, and it may vary between peptides.
What the evidence actually supports
The data across these seven studies paints a consistent picture with some inconvenient truths:
GH peptides reliably increase lean mass. MK-677 increased fat-free mass in both obese men and elderly adults. This is the most reproducible finding.
GH peptides do not reliably reduce fat in humans. Neither MK-677 trial showed significant fat loss. The only human fat reduction data comes from tesamorelin in HIV lipodystrophy, a specialized clinical context.
AOD-9604 works in rodents but failed in humans. The fragment specifically designed for fat loss passed animal testing and failed the human trial.
Appetite stimulation offsets lipolysis. GHS-receptor agonists like MK-677 increase appetite through ghrelin receptor activation. This built-in counterbalance likely explains why raising GH does not automatically produce fat loss.
Selectivity varies. Ipamorelin raises only GH; GHRP-2 and GHRP-6 also raise cortisol and prolactin; hexarelin may affect fat through non-GH pathways. These differences matter for body composition outcomes but have not been compared in controlled fat-loss trials.
Comparing GH peptides to GLP-1 agonists and body composition changes highlights the gap. GLP-1 drugs produce 15-20% weight loss in clinical trials. GH peptides produce weight gain with favorable compositional shifts. These are fundamentally different mechanisms aimed at different goals.
Limitations across the evidence base
Small sample sizes constrain nearly every study cited here. The largest MK-677 trial had 65 participants. Most studies lasted weeks to months. Long-term safety data for GH peptide use in body composition is sparse.
Most animal studies used genetically obese models (ob/ob mice, Zucker rats) that do not reflect the metabolic complexity of human obesity. Diet-induced obesity models would be more translatable.
Publication bias is a concern. The AOD-9604 phase IIb failure was not published in a peer-reviewed journal. Negative results from GH peptide trials may be underrepresented in the literature.
The interaction between GH peptides and diet, exercise, and other hormones is almost entirely unstudied. Whether GH peptides amplify the effects of caloric restriction or exercise on fat oxidation remains unknown.
The Bottom Line
Growth hormone peptides consistently increase lean body mass and restore GH secretion, but the evidence for direct fat loss in humans is weak. MK-677 builds muscle without reducing fat in two controlled trials. AOD-9604 showed promise in rodents but failed its human trial. Tesamorelin reduces visceral fat in HIV lipodystrophy specifically. The gap between the theoretical lipolytic effects of GH and the actual fat loss observed with GH peptides reflects the complexity of human metabolism, particularly the appetite-stimulating effects of ghrelin receptor activation.